CN110746479B - Compound and preparation method and application thereof - Google Patents

Compound and preparation method and application thereof Download PDF

Info

Publication number
CN110746479B
CN110746479B CN201910968512.XA CN201910968512A CN110746479B CN 110746479 B CN110746479 B CN 110746479B CN 201910968512 A CN201910968512 A CN 201910968512A CN 110746479 B CN110746479 B CN 110746479B
Authority
CN
China
Prior art keywords
methyl
pyridyl group
compound
group
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201910968512.XA
Other languages
Chinese (zh)
Other versions
CN110746479A (en
Inventor
刘玉法
高修正
吕绪涛
高翔宇
孙彬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong Normal University
Original Assignee
Shandong Normal University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong Normal University filed Critical Shandong Normal University
Priority to CN201910968512.XA priority Critical patent/CN110746479B/en
Publication of CN110746479A publication Critical patent/CN110746479A/en
Application granted granted Critical
Publication of CN110746479B publication Critical patent/CN110746479B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides a compound, a preparation method and application thereof, wherein the compound has a structure shown in a formula (I):

Description

Compound and preparation method and application thereof
Technical Field
The invention relates to the field of biological medicines, and particularly relates to a compound and a preparation method and application thereof.
Background
The information in this background section is only for enhancement of understanding of the general background of the invention and is not necessarily to be construed as an admission or any form of suggestion that this information forms the prior art that is already known to a person of ordinary skill in the art.
Cholangiocarcinoma is a common biliary tract malignant tumor, with high malignancy, very poor prognosis, and increasing morbidity and mortality year by year (wangxian, et al, the clinical treatment progress of hepatoportal cholangiocarcinoma [ J ], electronic journal of Chinese liver surgery, 2018, 7(4): 253-containing 257). The common chemotherapy drugs in the clinic of bile duct cancer are 5-fluorouracil and cisplatin. When the 5-fluorouracil reaches 20ug/mL, the traditional Chinese medicine composition has a good effect of inhibiting the growth of human bile duct cancer QBC939 cells, and has side effects of bone marrow inhibition such as leukopenia and platelet drop, and gastrointestinal reactions such as inappetence, nausea, vomiting, stomatitis, gastritis, abdominal pain and diarrhea. When the cisplatin reaches 3.0 mu g/mL, the cisplatin has a good effect of inhibiting cell growth of human bile duct cancer QBC939, and mainly has severe digestive tract reactions such as nausea and vomiting, renal toxicity such as renal tubular injury, and more common neurotoxicity such as tinnitus and hearing loss caused by auditory nerve damage. Because biliary duct cancer has hidden onset and difficult early diagnosis and has late clinical symptoms, epidemiological studies show that only 10-15% of patients are likely to be cured by operation, and many patients find that the patients are in late stage, but the postoperative recurrence rate is still 50-60%, and the five-year survival rate is only 30%. At present, the treatment principle of the bile duct cancer still adopts a comprehensive treatment scheme mainly based on surgical resection, but only patients with deficiency of 1/3 can be surgically resected when the diagnosis is confirmed, the surgical prognosis is poor, and the combined chemotherapy has no ideal effect on locally advanced or metastatic unresectable bile duct cancer. Therefore, the development of new therapeutic drugs is urgently required.
Pancreatic cancer is a common pancreatic tumor, is a digestive tract malignant tumor with high malignancy degree and difficult diagnosis and treatment, and has 5-year survival rate of less than 1 percent. The early diagnosis rate of pancreatic cancer is low, the operative mortality rate is high, and the early diagnosis rate is one of the worst malignant tumors. At present, the main therapeutic drugs comprise fluorouracil, doxorubicin, ifosfamide, semustine, paclitaxel, gemcitabine, cisplatin and the like, but the clinical cure rate is very low, so that research and development of anti-pancreatic cancer drugs with better curative effect are very necessary.
Diosgenin (CAS number 512-06-1) is a steroid compound obtained by hydrolyzing and deglycosylating dioscin contained in rhizome of Dioscoreaceae plants such as Dioscorea zingiberensis, Dioscorea nipponica, Dioscorea panthaica and the like, and is an important raw material for synthesizing steroid hormone drugs and steroid contraceptives. Dioscin has certain anticancer activity (application of protodioscin in preparing medicine for resisting drug-resistant osteosarcoma CN201810091212.3), and has effects in treating lung cancer cell A549(Wei Y, et al. Anti-cancer effects of Dioscin on third peptides of human lung cells through inducing DNA and activating pathological cancer, 2013, 59), gastric cancer cell MGC-803 (Zhuao X, et al. patent effects of Dioscin induced cancer in vitro and human physiology, human epidermis 2016, 23), hepatocarcinoma cell Huh7(Hsieh M J, et al. liver infection treatment and cancer cell III) and cancer cell of human liver, cancer cell III, 2016, 21) has certain anticancer activity, diosgenin also has certain activity on sarcoma-180, hepatoma ascites type, mouse cervical cancer, ehrlich ascites carcinoma (new pharmaceutical use of diosgenin CN01129317.9), and diosgenin 3-amide nitrogen-containing derivatives have certain antitumor activity (a diosgenin antitumor derivative and its synthesis method CN 201711083013; gunn, et al, journal of western medicine, 2009,24,475; jianghongping, et al. pharmaceutical science, 2011,46, 539; zui chunkui, et al, journal of western medicine 2011,26, 423; dingxiao, et al. pharmaceutical newspapers, 2012,46, 539; wu Yak, et al, J.Huaxi Pharmacology, 2012,27,22), diosgenin 3-position derivatives can inhibit ocular vascular dysplasia (use of diosgenin-3-position derivatives CN201310325890.9), and amino acid diosgenin esters have anti-inflammatory and anti-tumor effects (diosgenin-3-position derivatives, preparation methods and uses CN 201210303318.8; foudao, et al, journal of western medicine, 2010,25,658), diosgenin amino acid derivatives have growth inhibitory effects to different degrees on human colon cancer cells Caco-2, human gastric adenocarcinoma cells, human lung adenocarcinoma cells, and human neuroblastoma cells (diosgenin amino acid derivatives and their use in preparing anti-tumor drugs CN 201410250801.3; the food safety quality detection report 2015,3,1061), diosgenin 3-glycoside such as pentaglycoside and disaccharide, has certain inhibiting effect on breast cancer cells and human liver cancer cells.
Disclosure of Invention
Specifically, the invention has the following technical scheme:
in a first aspect of the invention, the invention provides a compound having the structure shown in formula (I):
Figure BDA0002231304400000031
wherein R is an unsubstituted or substituted nitrogen-containing heterocyclic group; the nitrogen heterocyclic group is a five-membered or six-membered nitrogen-containing aliphatic heterocyclic ring or a nitrogen-containing aromatic heterocyclic ring; the substituent is selected from alkyl, halogenated alkyl, carboxyl and halogen; the halogen is selected from F, Cl, Br and I.
Also, the present invention provides pharmaceutically acceptable salts of the compounds of formula (I).
Examples of the "pharmaceutically acceptable salt" include, for example, inorganic acid salts such as hydrochloride, hydrobromide, sulfate, phosphate and nitrate; organic acid salts such as acetate, propionate, oxalate, succinate, lactate, malate, tartrate, citrate, maleate, fumarate, methanesulfonate, benzenesulfonate, p-toluenesulfonate and ascorbate; inorganic base salts such as sodium salt, potassium salt, calcium salt, zinc salt, magnesium salt and aluminum salt; and organic base salts such as arginine salt, benzathine salt, choline salt, diethylamine salt, dialcohol amine salt, glycinate salt, lysine salt, meglumine salt, ethanolamine salt, and tromethamine salt.
In an embodiment of the invention, the nitrogen-containing heterocycle is selected from pyrrole, thiazole, imidazole, pyrazole, oxazole, isoxazole, pyridine, pyrimidine, pyridazine, pyrazine and piperidine.
In an embodiment of the invention, the substituents are selected from C1-3Alkyl, trifluoromethyl and carboxyl; the alkyl group is in particular methyl.
In embodiments of the invention the substitution is mono-or polysubstituted, for example, in some embodiments of the invention the nitrogen containing heterocycle is isoxazole, which is disubstituted with methyl in the positions C-3 and C-5 respectively of isoxazole, then R is 3, 5-dimethylisoxazol-4-yl, which can representIs composed of
Figure BDA0002231304400000032
The nitrogen-containing heterocycle is isoxazole, which is trisubstituted by methyl, the substituted positions are respectively C-3 position, C-4 position and C-5 position of the isoxazole, and R is 3, 5-dimethyl isoxazolyl-4-methyl and can be expressed as
Figure BDA0002231304400000033
In some embodiments of the invention, the nitrogen-containing heterocycle is unsubstituted, then R is selected from 2-pyrrolyl, 3-pyrrolyl, 2-imidazolyl, 4-imidazolyl, 3-pyrazolyl, 4-pyrazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 3-pyridazinyl, 4-pyridazinyl, and 2-pyrazinyl.
In some embodiments of the invention, R is selected from the group consisting of: 2-pyrrolyl, 3-pyrrolyl, 2-methyl-4-pyrrolyl, 2-imidazolyl, 4-methyl-2-imidazolyl, 2-methyl-4-imidazolyl, 3-pyrazolyl, 4-pyrazolyl, 5-methyl-3-pyrazolyl, 3-methyl-4-pyrazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 2-oxazolylmethyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 4-isoxazolyl, 3, 5-dimethylisoxazolyl-4-methyl, 2-imidazolyl, 4-pyrazolyl, 4-thiazolyl, 5-thiazolyl, 2-thiazolyl, 4-oxazolyl, 3-dimethylisoxazolyl-4-methyl, 2-oxazolyl, 3-dimethylisoxazolyl, 4-methyl, and mixtures thereof, 2-pyridyl group, 3-pyridyl group, 4-pyridyl group, 3-methyl-2-pyridyl group, 4-methyl-2-pyridyl group, 5-methyl-2-pyridyl group, 2-methyl-3-pyridyl group, 4-methyl-3-pyridyl group, 5-methyl-3-pyridyl group, 2-methyl-4-pyridyl group, 3-trifluoromethyl-2-pyridyl group, 4-trifluoromethyl-2-pyridyl group, 5-trifluoromethyl-2-pyridyl group, 2-trifluoromethyl-3-pyridyl group, 4-trifluoromethyl-3-pyridyl group, 5-trifluoromethyl-3-pyridyl group, 3-trifluoromethyl-pyridyl group, 3-pyridyl group, 4-trifluoromethyl-2-pyridyl group, 3-pyridyl group, 4-trifluoromethyl-pyridyl group, 3-, 2-trifluoromethyl-4-pyridyl group, 3-carboxy-2-pyridyl group, 4-carboxy-2-pyridyl group, 5-carboxy-2-pyridyl group, 2-carboxy-3-pyridyl group, 4-carboxy-3-pyridyl group, 5-carboxy-3-pyridyl group, 2-carboxy-4-pyridyl group, 3-pyridylmethyl group, 4-pyridylmethyl group, 2-pyrimidyl group, 4-pyrimidyl group, 5-pyrimidyl group, 4-methyl-2-pyrimidyl group, 5-methyl-2-pyrimidyl group, 2-methyl-4-pyrimidyl group, 3-carboxy-2-pyridyl group, 5-carboxy-3-pyridyl group, 2-methyl-5-pyrimidinyl, 2-pyrimidylmethyl, 4-pyrimidylmethyl, 5-pyrimidylmethyl, 3-pyridazinyl, 4-methyl-3-pyridazinyl, 5-methyl-3-pyridazinyl, 3-methyl-4-pyridazinyl, 3-pyridazinylmethyl, 4-pyridazinylmethyl, 2-pyrazinyl, 3-methyl-2-pyrazinyl and 2-pyrazinylmethyl.
Further, the compounds of formula (I) of the present invention include the structures shown in table 1:
TABLE 1 Structure of the compound of formula (I) and HR-MS structural analysis thereof
Figure BDA0002231304400000041
Figure BDA0002231304400000051
Figure BDA0002231304400000061
Figure BDA0002231304400000071
Figure BDA0002231304400000081
Figure BDA0002231304400000091
Figure BDA0002231304400000101
In a second aspect of the invention, there is also provided a process for the preparation of a compound of formula (I), said process comprising reacting diosgenin as an initial reactant with RX to produce a compound of formula (I); wherein R is as defined above for the first aspect of the invention and X is halogen.
In an embodiment of the present invention, the method comprises dissolving diosgenin in a solvent, adding RX to react with an alkaline substance, and keeping the solution alkaline during the reaction to obtain the compound of formula (I).
In the embodiment of the invention, the reaction temperature is-20-300 ℃, and the reaction time is 0.1-72 h; preferably, the reaction temperature is-20 to 120 ℃, at which the reaction proceeds more easily.
In an embodiment of the present invention, the solvent is selected from one or more of water, methanol, ethanol (absolute ethanol is preferred), propanol, butanol, pentanol, glycerol, dichloromethane, chloroform, carbon tetrachloride, benzene, toluene, xylene, 1, 4-dioxane, 1, 2-dichloroethane, tetrahydrofuran, N-Dimethylformamide (DMF), and ethyl acetate and dimethyl sulfoxide (DMSO); preferably any one of toluene, absolute ethanol, methanol, n-propanol, isopropanol, n-butanol, ethyl acetate, butyl acetate, methylene chloride, carbon tetrachloride, DMF and tetrahydrofuran, in which the reaction proceeds more easily.
In an embodiment of the present invention, the solvent is used in an amount of 5-100L per mole of diosgenin dissolved in the solvent.
In an embodiment of the invention, the alkaline substance is selected from γ -Al2O3-Na、γ-Al2O3-K、γ-Al2O3-NaOH-Na、γ-Al2O3-NaOH-K、γ-Al2O3-KOH-Na、γ-Al2O3-KOH-K, sodium methoxide, sodium ethoxide, sodium propoxide, sodium butoxide, sodium amide, sodium metal, sodium hydride, sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium oxide, potassium oxide, calcium oxide, strontium carbonate, potassium carbonate, sodium carbonate, potassium phosphate, ammonia, ethylamine, diethylamine, triethylamine, methylamine, dimethylamine, trimethylamine, pyridine and piperidineOne or more of (a).
In some preferred embodiments, the alkaline material is sodium hydride, potassium hydride, sodium ethoxide, strontium carbonate, potassium carbonate, γ -Al2O3-K, potassium carbonate, triethylamine, sodium tert-butoxide, sodium ethoxide, gamma-Al2O3KOH-Na or diethylamine, the reaction proceeds more easily in the presence of these basic substances.
In an embodiment of the present invention, the molar ratio of the diosgenin, RX, and the alkaline substance is 1: (0.1-10): (0.01-10), preferably 1 (1.0-1.2): (0.6-1.0).
In some embodiments of the present invention, the weight ratio of the diosgenin, RX and the alkaline substance is (4-20): (1.5-10): (0.01-5).
In an embodiment of the present invention, the preparation method of the compound of formula (I) according to the present invention further comprises detecting the end point of the reaction by chromatography, standing to room temperature after the reaction is finished, and separating and purifying to prepare the compound of formula (I).
In an embodiment of the present invention, the separation and purification method is selected from a combination of one or more of filtration, resin treatment, water washing, distillation, crystallization, extraction, activated carbon treatment, molecular sieve treatment, and chromatography.
The separation and purification method of the invention can be as follows: for example, in some embodiments, TLC detects the total reaction of diosgenin, heats to room temperature, adds water, extracts with dichloromethane, chloroform, acetone or ethyl acetate for 1 to more times, such as 3 times (e.g., 50mL × 3-300mL × 3), follows the reaction and separation and purification process of the product by TLC, recovers the extract, and dries the solid substance, such as at 60 ℃, for 4h to obtain the target product.
For example, in some embodiments, the separation and purification method may be: detecting all reactions of diosgenin by HPLC, distilling off solvent until liquid volume is reduced to 1/4, cooling and crystallizing overnight, such as cooling to 5 deg.C and crystallizing overnight, filtering, tracking reaction and product separation and purification process by HPLC, and drying solid, such as drying at 60 deg.C for 4 hr, to obtain target product.
For example, in some further embodiments, the separation and purification method may be: detecting the total reaction of diosgenin by HPLC, reducing pressure to remove solvent, performing chromatography, such as chromatography with chromatography column, eluting with ethyl acetate-ethanol (v/v ═ 10:1) or dichloromethane-methanol (v/v ═ 5:1), tracking the separation and purification process of reaction and product by HPLC, collecting and combining product fractions, and evaporating solvent by rotary evaporator (such as at 60 deg.C) to obtain the target product.
In a third aspect of the invention, the present invention also provides a composition comprising a compound of formula (I) as described in the above first aspect of the invention or a pharmaceutically acceptable salt thereof.
In a fourth aspect of the invention, the invention also provides a pharmaceutical formulation comprising a compound of formula (I) as described in the above first aspect of the invention or a pharmaceutically acceptable salt thereof or a composition comprising said compound of formula (I) or a salt thereof, together with at least one pharmaceutical carrier or adjuvant.
The pharmaceutical compositions of the present invention are generally safe, non-toxic and biologically desirable, the pharmaceutically acceptable carriers or excipients of the present invention are non-toxic and safe, and their combinations with the compounds of the present invention are also non-toxic and safe. The pharmaceutically acceptable carriers and excipients of the present invention are generally well known to those skilled in the art or can be determined by those skilled in the art based on the actual circumstances. Examples of suitable carriers and excipients include glucose, water, glycerol, ethanol, propylene glycol, corn starch, gelatin, lactose, sucrose, alginic acid, microcrystalline cellulose, kaolin, mannitol, dicalcium phosphate, sodium chloride, croscarmellose sodium and sodium starch glycolate and the like polysorbate 80, polyethylene glycol 300, polyethylene glycol 400, cyclodextrins or derivatives thereof such as ((2-hydroxypropyl) -cyclodextrin) and (2-hydroxyethyl) -cyclodextrin, which are also known as HPCD, pegylated castor oil, poloxamers such as poloxamer 407 or 188; hydrophilic carriers, hydrophobic carriers, or combinations thereof, and the like. Hydrophobic carriers include, for example, fat emulsions, lipids, pegylated phospholipids, biocompatible polymers, lipid spheres, liposomes, vesicles, polymer matrices, particles, and the like. Furthermore, one skilled in the art will appreciate that diluents are included within the term carrier and adjuvant.
The amount of carrier or adjuvant in the pharmaceutical composition may be from 1% to 98% by weight, usually about 80% by weight. For convenience, the local anesthetic, preservative, buffer, etc. may be dissolved directly in the vehicle.
Pharmaceutical compositions of the compounds of the present invention may be administered in any manner selected from: oral, aerosol inhalation, rectal, nasal, vaginal, topical, parenteral such as subcutaneous, intravenous, intramuscular, intraperitoneal, intrathecal, intraventricular, intrasternal or intracranial injection or infusion, or by means of an explanted reservoir, with oral, intramuscular, intraperitoneal or intravenous administration being preferred. The pharmaceutical dosage form can be a liquid dosage form, a solid dosage form. The liquid dosage form can be true solution, colloid, microparticle, emulsion, or mixed suspension. Other dosage forms such as tablet, capsule, dripping pill, aerosol, pill, powder, solution, suspension, emulsion, granule, suppository, lyophilized powder for injection, clathrate, landfill, patch, liniment, etc.
In a fifth aspect, the present invention also provides the use of a compound of formula (I) as described in the above first aspect of the present invention or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of formula (I) or a salt thereof, or a pharmaceutical formulation comprising a compound of formula (I) or a salt thereof, in the manufacture of a medicament for the treatment of cancer; in an embodiment of the invention, the cancer is preferably pancreatic cancer and/or cholangiocarcinoma.
In some embodiments of the invention, the inhibition rate of 0.2ug/mL of the compound of formula (I) of the invention on the proliferation of bile duct cancer cells QBC-939 is higher than 70%, and can reach 95%; the inhibition rate of 0.2ug/mL of the compound shown in the formula (I) on the proliferation of human pancreatic cancer cells PANC-1 is higher than 70% and can reach 95%. The activity of the compound of the invention is far higher than that of 5-fluorouracil used clinically.
Detailed Description
The invention will be further illustrated with reference to the following specific examples. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. The experimental procedures, in which specific conditions are not noted in the following examples, are generally carried out according to conventional conditions or according to conditions recommended by the manufacturers.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. The reagents or starting materials used in the present invention can be purchased from conventional sources, and unless otherwise specified, the reagents or starting materials used in the present invention can be used in a conventional manner in the art or in accordance with the product specifications. In addition, any methods and materials similar or equivalent to those described herein can be used in the methods of the present invention. The preferred embodiments and materials described herein are intended to be exemplary only.
Example 1
Weighing 4.2g of diosgenin and 0.5g of sodium hydride, dissolving in 500mL of 100mL of absolute ethanol, adding 1.5g of 2-chloropyrrole, stirring and freezing to-20 ℃, keeping the temperature and stirring for reaction for 72h, detecting the total reaction of the diosgenin by TLC (a developing agent: petroleum ether-ethyl acetate (1:1) and a color developing agent: 5% phosphomolybdic acid ethanol solution), distilling out the ethanol, cooling to room temperature, adding 50mL of water, extracting for 3 times (60mL multiplied by 3) by dichloromethane, recovering the dichloromethane from an extract, tracking the reaction by TLC and the separation and purification process of a product, and drying the solid at 60 ℃ for 4h to obtain 3.2g of a light yellow powdery product. Melting point of the target product: 192.5-194.5 ℃ of the total weight of the mixture,13C NMR(CDCl3100MHz) delta 143.56,140.83,121.85,119.64,118.34,108.61,107.92,82.95,82.33,66.94,62.82,56.64,50.81,42.15,40.71,40.13,39.24,37.73,37.52,32.86,32.26,32.05,31.31,30.35,29.14,28.86,21.13,19.37,17.56,15.50, 14.82. TOF-HRMS: m/e (479.6925), formula: c31H45O3N, compound 1 in table 1.
Compound 2(R is 3-pyrrolyl) can be prepared in a similar manner to example 1, using the appropriate halogenated nitrogen-containing heterocyclic group (halogen may be Cl or Br).
Example 2
Weighing diosgenin 4.2g and potassium hydride 1.0g, and dissolving in 100mL methanolPutting 500mL of the mixture into a three-neck flask, adding 1.5g of 2-methyl-3-chloro-pyrrole, stirring and heating the mixture to 25 ℃, keeping the temperature and stirring the mixture for reaction for 36h, detecting the total reaction of diosgenin by TLC (developing agent: petroleum ether-ethyl acetate (1:1) and color developing agent: 5% phosphomolybdic acid ethanol solution), distilling out methanol, cooling the methanol to room temperature, adding 50mL of water, extracting the mixture for 3 times (60mL multiplied by 3) with dichloromethane, recovering the dichloromethane from an extract, tracking the reaction and the separation and purification process of the product by TLC, and drying the solid substance for 4h at 60 ℃ to obtain 3.4g of a light yellow powdery product. Melting point of the target product: 191.7-193.9 ℃ of the total weight of the composition,13C NMR(CDCl3100MHz) delta 140.80,129.86,121.82,119.61,118.05,108.21,107.83,82.92,82.50,66.91,62.79,56.61,50.78,42.12,40.68,40.10,39.21,37.70,37.49,32.83,32.20,32.02,31.28,30.32,29.11,28.83,21.10,19.34,17.53,15.47,14.79, 11.95. TOF-HRMS: m/e (493.7189), formula: c32H47O3N, compound 3 in table 1.
Compound 4(R ═ 2-methyl-4-pyrrolyl) can be prepared according to a similar procedure to example 2, using the appropriate halogenated nitrogen-containing heterocyclyl group (halogen can be Cl or Br).
Example 3
Weighing diosgenin 4.2g and sodium ethoxide 0.8g, dissolving in 100mL of n-propanol in a 500mL three-neck flask, adding 2-chloroimidazole 1.5g, stirring and heating at 75 ℃, keeping the temperature and stirring for reaction for 48h, detecting the total reaction of the diosgenin by TLC (a developing agent: petroleum ether-ethyl acetate (1:1), a color developing agent: 5% phosphomolybdic acid ethanol solution), distilling out the n-propanol, cooling to room temperature, separating by using a silica gel chromatographic column, eluting by using ethyl acetate-ethanol (such as 10:1), collecting a product fraction, carrying out rotary evaporation on the solvent to obtain a solid, tracking the separation and purification processes of the reaction and the product by TLC, and drying at 60 ℃ for 4h to obtain a light yellow powdery product 3.5 g. Melting point of the target product: 195.1-196.8 ℃ of the total weight of the composition,13C NMR(CDCl3100MHz) delta 150.11,140.81,127.84,127.81,121.83,119.62,82.93,81.28,66.92,62.80,56.62,50.79,42.13,40.69,40.11,39.22,37.71,37.50,32.84,32.21,32.03,31.29,30.33,29.12,28.84,21.11,19.35,17.54,15.48, 14.80. TOF-HRMS: m/e (480.6806), formula: c30H44O3N2I.e. compound 5 in table 1.
Compound 6(R ═ 4-imidazolyl) can be prepared in a similar manner to example 3, using the appropriate halogenated nitrogen-containing heterocyclic group (halogen can be Cl or Br).
Example 4
Weighing diosgenin 4.2g and strontium carbonate 0.05g, dissolving in 100mL n-propanol in 500mL three-neck flask, adding 2-methyl-4-bromo-imidazole 2.0g, heating and stirring at 95 deg.C, maintaining the temperature and stirring for reaction for 18h, detecting total reaction of diosgenin by TLC, evaporating solvent under reduced pressure, cooling to room temperature, adding 50mL water, extracting with acetone for 3 times (50mL × 3), extracting with anhydrous Na2SO4Drying for 8h, filtering, recovering acetone from the filtrate to obtain solid, tracking reaction by TLC, separating and purifying the product, and drying the solid at 60 deg.C for 4h to obtain light yellow powder 3.7 g. Melting point of the target product: the temperature of the mixture is 194.5 to 196.6 ℃,13C NMR(101MHz,CDCl3) δ 145.72,140.82,122.25,122.04,121.84,119.63,82.94,81.62,66.93,62.81,56.63,50.80,42.14,40.70,40.12,39.23,37.72,37.51,32.85,32.22,32.04,31.30,30.34,29.13,28.85,21.12,19.36,17.95,17.55,15.49, 14.81. TOF-HRMS: m/e (494.7071), formula: c31H46O3N2I.e. compound 8 in table 1.
Compound 7(R ═ 4-methyl-2-imidazolyl) was prepared in a similar manner to example 4, using the appropriate halogenated nitrogen-containing heterocyclic group (halogen may be Cl or Br).
Example 5
Weighing 4.2g of diosgenin and 1.5g of potassium carbonate, dissolving in 100mL of carbon tetrachloride in a 500mL three-neck flask, adding 2.0g of 4-bromo-pyrazole, stirring and heating to boil (97 ℃), keeping the temperature and stirring for reaction for 16h, detecting the total reaction of the diosgenin by TLC, decompressing and distilling off the solvent, cooling to room temperature, adding 100mL of water, adsorbing by 101 macroporous resin, eluting by 95%, collecting product fractions, recovering ethanol to obtain a solid, tracking the separation and purification process of the reaction and the product by TLC, and drying the solid at 60 ℃ for 4h to obtain 2.9g of a light yellow powdery product. Purpose productMelting point of the substance: the temperature of the mixture is 195.4-197.3 ℃,13C NMR(100MHz,CDCl3) δ 141.23,140.93,121.95,119.74,114.45,114.44,83.05,81.25,67.04,62.92,56.74,50.91,42.25,40.81,40.23,39.34,37.83,37.62,32.96,32.33,32.15,31.41,30.45,29.24,28.96,21.23,19.47,17.66,15.60, 14.92. TOF-HRMS: m/e (480.6802), formula: c30H44O3N2Compound 10 in table 1.
Compound 9(R ═ 3-pyrazolyl) can be prepared according to a similar manner to example 5, using an appropriate halogenated nitrogen-containing heterocyclic group (halogen may be Cl or Br).
Example 6
Weighing diosgenin 4.2g and gamma-Al2O3Dissolving 0.5g of-K in 100mL of isopropanol in a 500mL three-neck flask, adding 2.2g of 5-methyl-3-bromo-pyrazole, heating and stirring at 98 ℃, keeping the temperature and stirring for reaction for 24 hours, detecting all reactions of diosgenin by TLC (developing agent: petroleum ether-ethyl acetate (1:1) and color developing agent: 5% phosphomolybdic acid ethanol solution), distilling the solvent under reduced pressure, cooling to room temperature, adding 50mL of water, extracting for 3 times (50mL × 3) with acetone, and extracting the extract with anhydrous Na2SO4Drying for 8h, filtering, recovering acetone from the filtrate to obtain solid, tracking reaction by TLC, separating and purifying the product, and drying the solid at 60 deg.C for 4h to obtain light yellow powder 3.2 g. Melting point of the target product: 192.5-193.9 ℃ of the weight percentage,13C NMR(101MHz,CDCl3) δ 169.15,141.95,140.94,121.96,119.75,97.24,83.06,81.15,67.05,62.93,56.75,50.92,42.26,40.82,40.24,39.35,37.84,37.63,32.97,32.34,32.16,31.42,30.46,29.25,28.97,21.24,19.48,17.67,15.61,14.93, 13.46. TOF-HRMS: m/e (494.7071), formula: c31H46O3N2I.e. compound 11 in table 1.
Compound 12(R ═ 3-methyl-4-pyrazolyl) can be prepared according to a similar manner to that of example 6, using an appropriate halogenated nitrogen-containing heterocyclic group (halogen may be Cl or Br).
Example 7
Weighing diosgenin 4.2g and potassium carbonate 1.5g, and dissolving in 100mLAdding n-butanol into 500mL three-neck flask, adding 1.8g of 2-bromo-thiazole, heating and stirring at 100 deg.C, maintaining the temperature and stirring for reaction for 12h, detecting total reaction of diosgenin by TLC (developing agent: petroleum ether-ethyl acetate (1:1), developer: 5% phosphomolybdic acid ethanol solution), distilling off solvent under reduced pressure, cooling to room temperature, adding 50mL of water, extracting with acetone for 3 times (50mL × 3), extracting with anhydrous Na2SO4Drying for 8h, filtering, recovering acetone from the filtrate to obtain solid, tracking reaction by TLC, separating and purifying the product, and drying the solid at 60 deg.C for 4h to obtain light yellow powder 3.9 g. Melting point of the target product: 195.7-197.5 ℃ of the total weight of the feed,13C NMR(101MHz,CDCl3) δ 154.12,142.65,140.91,121.93,119.72,118.64,83.03,81.15,67.02,62.90,56.72,50.89,42.23,40.79,40.21,39.32,37.81,37.60,32.94,32.31,32.13,31.39,30.43,29.22,28.94,21.21,19.45,17.64,15.58, 14.90. TOF-HRMS: m/e (497.7311), formula: c30H43O3NS, compound 13 in table 1.
Compound 14(R ═ 4-thiazolyl) and compound 15(R ═ 5-thiazolyl) can be prepared according to a similar procedure to example 7, using the appropriate halogenated nitrogen-containing heterocyclic group (halogen can be Cl or Br), respectively.
Example 8
Weighing 4.2g of diosgenin and 1.5g of potassium carbonate, dissolving in 100mL of toluene in a 500mL three-neck flask, adding 1.8g of 4-bromo-oxazole, heating and stirring for 90 ℃, keeping the temperature and stirring for reaction for 12h, detecting the total reaction of the diosgenin by TLC (a developing agent: petroleum ether-ethyl acetate (1:1), a color developing agent: 5% phosphomolybdic acid ethanol solution), distilling the solvent out under reduced pressure, cooling to room temperature, adding 100mL of water, adsorbing by 101 macroporous resin, eluting by 95% of ethanol, collecting product fractions, distilling the solvent to obtain a solid, tracking the separation and purification process of the reaction and the product by TLC, drying the solid at 60 ℃ for 4h to obtain 4.0g of a light yellow powdery product. Melting point of the target product: the temperature of the mixed solution is between 191.4 and 193.3 ℃,13C NMR(101MHz,CDCl3)δ151.43,140.92,138.14,125.62,121.94,119.73,83.04,81.19,67.03,62.91,56.73,50.90,42.24,40.80,40.22,39.33,37.82,37.61,32.95,32.32,32.14,31.40,30.44,29.23,28.95,21.22,19.46,17.65,15.59,14.91. TOF-HRMS: m/e (481.6651), formula: c30H43O4N, compound 17 in table 1.
Compound 16(R ═ 2-oxazolyl) and compound 18(R ═ 5-oxazolyl) can be prepared according to a similar procedure to that of example 8, using the appropriate halogenated nitrogen-containing heterocyclic group (halogen may be Cl or Br).
Example 9
Weighing diosgenin 4.2g and potassium carbonate 1.5g, dissolving in tetrahydrofuran 100mL in a 500mL three-neck flask, adding 2-oxazolylmethyl bromide 2.0g, heating and stirring at 50 deg.C, maintaining the temperature and stirring for reaction for 12h, detecting diosgenin by TLC (developing agent: petroleum ether-ethyl acetate (1:1), developer: 5% phosphomolybdic acid ethanol solution), reacting, evaporating solvent under reduced pressure, cooling to room temperature, adding water 50mL, extracting with acetone for 3 times (50mL × 3), extracting with anhydrous Na2SO4Drying for 8h, filtering, recovering acetone from the filtrate to obtain solid, tracking reaction by TLC, separating and purifying the product, and drying the solid at 60 deg.C for 4h to obtain light yellow powder 3.7 g. Melting point of the target product: the temperature of the mixture is between 190.4 and 192.1 ℃,13C NMR(101MHz,CDCl3) δ 150.62,140.89,139.70,127.06,121.91,119.70,87.15,83.06,67.81,67.00,62.88,56.70,50.87,42.21,40.77,40.19,39.30,37.79,37.58,32.92,32.29,32.11,31.37,30.41,29.30,28.92,21.19,19.43,17.62,15.56, 14.88. TOF-HRMS: m/e (495.6918), formula: c31H45O4N, compound 19 in table 1.
Example 10
Weighing diosgenin 4.2g, dissolving in ethyl acetate 80mL in a three-neck flask 500mL, adding triethylamine 10mL and 4-chloro-isoxazole 1.8g, stirring, freezing to-10 deg.C, keeping the temperature for reaction for 72h, detecting total reaction of diosgenin by TLC (developing agent: petroleum ether-ethyl acetate (1:1), developer: 5% phosphomolybdic acid ethanol solution), heating to room temperature, keeping the temperature for 2h, steaming under reduced pressure to liquid volume of 20mL, cooling to 5 deg.C, crystallizing overnight, filtering, tracking the reaction and separation and purification process of the product by TLC, drying the solid at 60 deg.C for 4h to obtain light yellow powdered product 2.9g. Melting point of the target product: the temperature of the mixture is between 190.2 and 192.0 ℃,13C NMR(101MHz,CDCl3) δ 158.83,150.07,140.87,121.89,119.68,100.56,83.04,82.10,66.98,62.86,56.68,50.85,42.19,40.75,40.17,39.28,37.77,37.56,32.90,32.27,32.09,31.35,30.39,29.28,28.90,21.17,19.41,17.60,15.54, 14.86. TOF-HRMS: m/e (481.6647), formula: c30H43O4N, compound 21 in table 1.
Compound 20(R ═ 3-isoxazolyl), compound 22(R ═ 5-isoxazolyl), and compound 23(R ═ 4-isoxazolylmethyl) were each prepared according to a similar procedure to that of example 10, using an appropriate halogenated nitrogen-containing heterocyclic group (halogen may be Cl or Br).
Example 11
Weighing 4.2g of diosgenin, dissolving in 80mL of DMF (dimethyl formamide) in a 500mL three-neck flask, adding 10mL of triethylamine and 2.0g of 3, 5-dimethyl-4-chloromethyl isoxazole, stirring, freezing to 0 ℃, preserving heat for reaction for 36h, detecting the total reaction of the diosgenin by TLC (developing agent: petroleum ether-ethyl acetate (1:1) and color developing agent: 5% phosphomolybdic acid ethanol solution), heating to room temperature, preserving heat for 2h, evaporating under reduced pressure until the liquid volume is 20mL, cooling to 5 ℃, crystallizing overnight, filtering, tracking the separation and purification process of the reaction and the product by TLC, and drying the solid at 60 ℃ for 4h to obtain 3.3g of light yellow powder product. Melting point of the target product: at the temperature of 189.5-191.2 ℃,13C NMR(101MHz,CDCl3) δ 158.92,150.05,140.85,121.87,119.66,100.50,83.02,81.85,66.96,62.84,56.66,50.83,42.17,40.73,40.15,39.26,37.75,37.54,32.88,32.25,32.07,31.33,30.37,29.26,28.88,21.15,19.39,17.58,15.52,14.84,10.61, 9.27. TOF-HRMS: m/e (523.7451), formula: c33H49O4N, compound 24 in table 1.
Example 12
Weighing diosgenin 4.2g, dissolving in 80mL butyl acetate in 500mL three-neck flask, adding sodium ethoxide 1.0g and 2-chloro-pyridine 2.0g, stirring, reacting at room temperature for 24h, detecting diosgenin by TLC (developing agent: petroleum ether-ethyl acetate (1:1), developer: 5% phosphomolybdic acid ethanol solution), reacting, and steaming under reduced pressureThe liquid volume is 20mL, the liquid is cooled to 5 ℃, crystallized overnight, filtered, TLC tracks the reaction and the separation and purification process of the product, and the solid is dried at 60 ℃ for 4h to obtain 3.4g of a light yellow powder product. Melting point of the target product: 192.5-194.3 ℃ of the total weight of the mixture,13C NMR(101MHz,CDCl3) δ 163.42,146.81,140.84,138.10,121.86,119.65,116.75,109.21,83.01,81.54,66.95,62.83,56.65,50.82,42.16,40.72,40.14,39.25,37.74,37.53,32.87,32.24,32.06,31.32,30.36,29.25,28.87,21.14,19.38,17.57,15.51, 14.83. TOF-HRMS: m/e (491.7038), formula: c32H45O3N, compound 25 in table 1.
Compound 26(R ═ 3-pyridyl) and compound 27(R ═ 4-pyridyl) can be prepared according to a similar manner to example 12, using an appropriate halogenated nitrogen-containing heterocyclic group (halogen may be Cl or Br).
Example 13
Weighing 4.2g of diosgenin, dissolving in 200mL of dichloromethane in a 500mL three-neck flask, adding 1.8g of sodium tert-butoxide and 2.5g of 2-methyl-4-iodo-pyridine, stirring, reacting at room temperature for 24h, detecting all reactions of the diosgenin by TLC (developing agent: petroleum ether-ethyl acetate (1:1) and developer: 5% phosphomolybdic acid ethanol solution), evaporating under reduced pressure until the liquid volume is 20mL, cooling to 5 ℃, crystallizing overnight, filtering, tracking the reaction and the separation and purification process of the product by TLC, and drying the solid at 60 ℃ for 4h to obtain 4.0g of a light yellow powder product. Melting point of the target product: the temperature of the mixed solution is between 191.5 and 193.3 ℃,13C NMR(101MHz,CDCl3) δ 158.91,158.30,149.52,140.80,121.82,119.61,112.95,105.52,82.97,81.62,66.91,62.79,56.61,50.78,42.12,40.68,40.10,39.21,37.70,37.49,32.83,32.20,32.02,31.28,30.32,29.21,28.83,24.22,21.10,19.34,17.53,15.46, 14.79. TOF-HRMS: m/e (505.7306), formula: c33H47O3N, compound 34 in table 1.
Compound 28(R ═ 3-methyl-2-pyridyl), compound 29(R ═ 4-methyl-2-pyridyl), compound 30(R ═ 5-methyl-2-pyridyl), compound 31(R ═ 2-methyl-3-pyridyl), compound 32(R ═ 4-methyl-3-pyridyl), compound 33 (5-methyl-3-pyridyl), and compound 35(R ═ 3-methyl-4-pyridyl) can be prepared according to a similar method to example 13, using an appropriate halogenated nitrogen-containing heterocyclic group (halogen may be Cl or Br).
Example 14
Weighing diosgenin 4.2g and sodium ethoxide 0.8g, dissolving in 100mL of n-propanol in a 500mL three-neck flask, adding 3-trifluoromethyl-2-bromo-pyridine 2.5g, stirring and heating at 60 ℃, keeping the temperature and stirring for reaction for 36h, detecting the total reaction of the diosgenin by TLC (a developing agent: petroleum ether-ethyl acetate (1:1) and a color developing agent: 5% phosphomolybdic acid ethanol solution), evaporating the n-propanol, cooling to room temperature, adding 80mL of water, extracting for 3 times (100mL multiplied by 3) by using trichloromethane, tracking the reaction by TLC and the separation and purification process of a product, recovering the trichloromethane from an extract, and drying a solid at 60 ℃ for 4h to obtain a light yellow powdery product 3.0 g. Melting point of the target product: the temperature of the mixture is between 201.1 and 202.7 ℃,13C NMR(CDCl3100MHz) delta 159.90,144.52,140.90,137.23,125.15,121.92,119.71,118.23,108.61,83.07,81.54,67.01,62.89,56.71,50.88,42.22,40.78,40.20,39.31,37.80,37.59,32.93,32.30,32.12,31.38,30.42,29.31,28.93,21.20,19.44,17.63,15.56, 14.89. TOF-HRMS: m/e (559.7014), formula: c33H44O3NF3Compound 36 in table 1.
Compound 37(R ═ 4-trifluoromethyl-2-pyridyl) and compound 38(R ═ 5-trifluoromethyl-2-pyridyl) can be prepared according to a similar procedure to that of example 14, using an appropriate halogenated nitrogen-containing heterocyclic group (halogen may be Cl or Br).
Example 15
Weighing diosgenin 4.2g and potassium carbonate 1.5g, dissolving in 100mL isopropanol in 500mL three-neck flask, adding 2-trifluoromethyl-4-bromo-pyridine 2.6g, heating and stirring at 110 deg.C, maintaining the temperature and stirring for 12h, detecting by TLC (developing agent: petroleum ether-ethyl acetate (1:1), developer: 5% phosphomolybdic acid ethanol solution) for total reaction, evaporating solvent under reduced pressure, cooling to room temperature, adding water 50mL, extracting with acetone for 3 times (50mL × 3), tracking reaction and product separation and purification process by TLC, extracting with anhydrous Na2SO4Drying for 8h, filtering, recovering acetone from the filtrate to obtain solid, and drying at 60 deg.C for 4h to obtain light yellow powder 3.3 g. Melting point of the target product: 102.9-1204.5 ℃ of the weight percentage,13C NMR(100MHz,CDCl3) δ 158.33,149.50,144.62,140.88,120.10,121.90,119.69,112.93,105.65,83.05,81.57,66.99,62.87,56.69,50.86,42.20,40.76,40.18,39.29,37.78,37.57,32.91,32.28,32.10,31.36,30.40,29.29,28.91,21.18,19.42,17.61,15.54, 14.87. TOF-HRMS: m/e (559.7030), formula: c33H44O3NF3I.e. compound 42 in table 1.
Compound 39(R ═ 2-trifluoromethyl-3-pyridyl), compound 40(R ═ 4-trifluoromethyl-3-pyridyl), compound 41(R ═ 5-trifluoromethyl-3-pyridyl), and compound 43(R ═ 3-trifluoromethyl-4-pyridyl) can be prepared according to a similar procedure to that of example 15, using an appropriate halogenated nitrogen-containing heterocyclic group (halogen may be Cl or Br).
Example 16
Weighing diosgenin 4.2g and gamma-Al2O3KOH-Na 0.5g was dissolved in 100mL of isopropanol in a 500mL three-necked flask, and 3-carboxy-2-chloro-pyridine 2.0g was added thereto, and the mixture was stirred under heating at 120 ℃ and kept warm for 24 hours, followed by HPLC (conditions for chromatography: Agilent Zorbax SB-C18(4.6 mm. times.150 mm,5um) as a column, acetonitrile-water (90: 10) as a mobile phase, and a flow rate of 1.0mL.min-1Detecting total reaction of diosgenin at detection wavelength of 203nm and column temperature of 35 deg.C, distilling off solvent under reduced pressure, cooling to room temperature, adding 50mL of water, extracting with acetone for 3 times (50mL × 3), tracking reaction and product separation and purification process by HPLC, and extracting with anhydrous Na2SO4Drying for 8h, filtering, recovering acetone from the filtrate to obtain solid, and drying the solid at 60 deg.C for 4h to obtain light yellow powder 3.5 g. Melting point of the target product: 177.5 to 179.2 ℃ of the mixture,13C NMR(101MHz,CDCl3) δ 169.35,161.20,149.81,140.89,139.02,121.91,119.70,119.11,110.83,83.06,81.21,66.70,62.88,56.70,50.87,42.21,40.77,40.19,39.30,37.79,37.58,32.92,32.29,32.11,31.37,30.41,29.30,28.92,21.19,19.43,17.62,15.55, 14.88. TOF-HRMS: m/e (535.7154), formula: c33H45O5N, compound 44 in table 1.
Compound 45(R ═ 4-carboxy-2-pyridyl), compound 46(R ═ 5-carboxy-2-pyridyl), compound 47(R ═ 2-carboxy-3-pyridyl), compound 48(R ═ 4-carboxy-3-pyridyl), compound 49(R ═ 5-carboxy-3-pyridyl), compound 50(R ═ 2-carboxy-3-pyridyl), compound 51(R ═ 3-carboxy-4-pyridyl) can be prepared according to a similar method to that of example 16, using an appropriate halogenated nitrogen-containing heterocyclic group (halogen may be Cl or Br).
Example 17
Weighing diosgenin 4.2g, dissolving in 80mL ethyl acetate in 500mL three-neck flask, adding triethylamine 10mL and 3-chloromethylpyridine 1.5g, stirring, freezing to-10 deg.C, reacting for 72h under constant temperature, and performing HPLC (chromatographic conditions: Agilent Zorbax SB-C18(4.6mm × 150mm,5um) on chromatographic column, acetonitrile-water (90: 10) as mobile phase, and flow rate of 1.0mL.min-1Detecting the total reaction of diosgenin at the detection wavelength of 203nm and the column temperature of 35 ℃), heating to room temperature, keeping the temperature for 2h, steaming under reduced pressure until the liquid volume is 20mL, cooling to 5 ℃, crystallizing overnight, filtering, tracing the reaction and the separation and purification process of the product by HPLC, and drying the solid at 60 ℃ for 4h to obtain 3.0g of a light yellow powdery product. Melting point of the target product: the temperature of the mixture is between 191.0 and 192.6 ℃,13C NMR(100MHz,CDCl3) δ 150.13,147.31,140.88,134.33,132.63,123.35,121.90,119.69,87.75,83.05,72.85,66.99,62.87,56.69,50.86,42.20,40.76,40.18,39.29,37.78,37.57,32.91,32.28,32.10,31.36,30.40,29.29,28.91,21.18,19.42,17.61,15.54, 14.87. TOF-HRMS: m/e (505.7301), formula: c33H47O3N, compound 52 in table 1.
Compound 53(R ═ 4-pyridylmethyl) can be prepared in a similar manner to example 17, using the appropriate halogenated nitrogen-containing heterocyclic group (halogen can be Cl or Br).
Example 18
Weighing diosgenin 4.2g, dissolving in dichloromethane 100mL, adding diethylamine 10mL and 4-chloropyrimidine 1.5g, stirring, reacting at 20 deg.C under heat preservation18h, HPLC (chromatographic conditions: Agilent Zorbax SB-C18(4.6 mm. times.150 mm,5um) on chromatographic column, acetonitrile-water (90: 10) as mobile phase, 1.0mL. min. flow rate-1Detecting the total reaction of diosgenin at the detection wavelength of 203nm and the column temperature of 35 ℃), evaporating dichloromethane until the liquid volume is reduced to 1/4, cooling to 5 ℃, crystallizing overnight, filtering, tracing the separation and purification process of the reaction and the product by HPLC, and drying the solid at 60 ℃ for 4 hours to obtain 3.1g of yellow powdery product. Melting point of the target product: 195.9-197.5 ℃ of the total weight of the feed,13C NMR(CDCl3100MHz) delta 168.43,157.55,157.34,140.93,121.95,119.74,108.72,83.05,81.57,67.04,62.92,56.74,50.91,42.25,40.81,40.23,39.34,37.83,37.62,32.96,32.33,32.15,31.41,30.45,29.24,28.96,21.23,19.47,17.66,15.60, 14.92. TOF-HRMS: m/e (492.6911), formula: c31H44O3N2Compound 55 in table 1.
Compound 54(R ═ 2-pyrimidinyl) and compound 56(R ═ 5-pyrimidinyl) can be prepared according to a similar procedure to that of example 18, using the appropriate halogenated nitrogen-containing heterocyclic group (halogen may be Cl or Br).
Example 19
Weighing diosgenin 4.2g, dissolving in dichloromethane 100mL, adding diethylamine 10mL and 2-methyl-4-bromo-pyrimidine 2.5g, stirring, reacting at 40 deg.C for 8h, and performing HPLC (chromatography conditions: Agilent Zorbax SB-C18(4.6mm × 150mm,5um) with mobile phase of acetonitrile-water (90: 10) and flow rate of 1.0mL. min-1Detecting the total reaction of diosgenin at the detection wavelength of 203nm and the column temperature of 35 ℃), evaporating dichloromethane until the liquid volume is reduced to 1/4, cooling to 5 ℃, crystallizing overnight, filtering, tracing the separation and purification process of the reaction and the product by HPLC, and drying the solid at 60 ℃ for 4 hours to obtain 3.0g of yellow powdery product. Melting point of the target product: 192.6-194.4 ℃ of the total weight of the mixture,13C NMR(CDCl3100MHz) delta 168.02,164.95,159.51,140.90,121.92,119.71,105.75,83.02,81.54,67.01,62.89,56.71,50.88,42.22,40.78,40.20,39.31,37.80,37.59,32.93,32.30,32.12,31.38,30.42,29.21,28.93,24.72,21.20,19.44,17.63,15.57, 14.89. TOF-HRMS: m/e (506.7180), formula: c32H46O3N2Compound 59 in table 1.
Compound 57(R ═ 4-methyl-2-pyrimidinyl), 58(R ═ 5-methyl-2-pyrimidinyl), and 60(R ═ 2-methyl-5-pyrimidinyl) were prepared according to a similar procedure to that of example 19, using the appropriate halogenated nitrogen-containing heterocyclic group (halogen may be Cl or Br).
Example 20
Weighing 16.8g of diosgenin and 0.8g of sodium hydride, dissolving in 400mL of methanol in a 1000mL three-neck flask, adding 5.8g of 2-chloromethylpyrimidine, stirring and heating at 65 ℃, keeping the temperature and stirring for reaction for 6 hours, detecting all reactions of the diosgenin by TLC, distilling out the methanol, cooling to room temperature, adding 150mL of water, extracting for 3 times (200mL multiplied by 3) by using dichloromethane, tracking the separation and purification processes of the reactions and the products by TLC, recovering the dichloromethane from the extract, and drying the solid at 60 ℃ for 4 hours to obtain 12.2g of a light yellow powdery product. Melting point of the target product: the temperature of between 187.6 and 189.3 ℃,13C NMR(CDCl3100MHz) delta 165.42,157.15,157.14,140.89,121.91,119.70,117.83,87.14,83.01,69.72,67.00,62.88,56.70,50.87,42.21,40.77,40.19,39.30,37.79,37.58,32.92,32.29,32.11,31.37,30.41,29.20,28.92,21.19,19.43,17.62,15.56, 14.88. TOF-HRMS: m/e (506.7179), formula: c32H46O3N2Compound 61 in table 1.
Compound 62(R ═ 4-pyrimidinylmethyl) can be prepared according to a similar procedure to example 20, using the appropriate halogenated nitrogen-containing heterocyclyl group (halogen can be Cl or Br).
Example 21
Weighing 16.8g of diosgenin and 2.1g of sodium ethoxide, dissolving in 400mL of absolute ethanol, adding 8.0g of 5-chloromethylpyrimidine into a 1000mL three-neck flask, stirring and heating at 78.5 ℃, keeping the temperature, stirring and reacting for 4 hours, detecting all reactions of the diosgenin by TLC, distilling off the absolute ethanol, cooling to room temperature, adding 120mL of water, extracting for 3 times (200mL multiplied by 3) by using trichloromethane, tracking the separation and purification processes of the reactions and the products by TLC, recovering the trichloromethane from the extract, and drying the solid at 60 ℃ for 4 hours to obtain 13.5g of a light yellow powdery product. Eyes of a userMelting point of the product of (1): 183.5-185.3 ℃ of the total weight of the mixture,13C NMR(CDCl3100MHz) delta 165.62,147.55,140.78,128.61,121.80,119.59,117.33,82.90,81.51,66.89,62.77,56.59,50.76,42.10,40.66,40.08,39.19,37.68,37.47,32.81,32.18,32.00,31.26,30.30,29.09,28.81,21.08,19.32,17.51,15.45, 14.77. TOF-HRMS: m/e (506.7180), formula: c32H46O3N2Compound 63 in table 1.
Example 22
Weighing 4.2g of diosgenin and 1.40g of potassium carbonate, dissolving in 100mL of propanol in a 500mL three-necked flask, adding 2.1g of 4-methyl-3-bromo-pyridazine, heating and stirring at 98 ℃, keeping the temperature and stirring for reaction for 4h, detecting by TLC (thin layer chromatography) all reactions of the diosgenin, distilling the solvent under reduced pressure, cooling to room temperature, adding 50mL of water, extracting for 3 times (100mL multiplied by 3) with acetone, carrying out TLC (thin layer chromatography) tracking reaction and separation and purification processes of a product, eluting the extract by a silica gel chromatographic column and dichloromethane-absolute ethyl alcohol (5: 1), collecting a product fraction, distilling the solvent, and drying the solid at 60 ℃ for 4h to obtain 3.5g of a light yellow powdery product. Melting point of the target product: 184.5-186.2 ℃ of water,13C NMR(101MHz,CDCl3) δ 159.81,140.79,136.65,131.11,128.03,121.81,119.60,82.91,81.84,66.90,62.78,56.60,50.77,42.11,40.67,40.09,39.20,37.69,37.48,32.82,32.19,32.01,31.27,30.31,29.10,28.82,21.09,19.33,17.52,15.46,15.40, 14.78. TOF-HRMS: m/e (506.7179), formula: c32H46O3N2Compound 66 in table 1.
Compound 64(R ═ 3-pyridazinyl), compound 65(R ═ 4-pyridazinyl), compound 67(R ═ 5-methyl-3-pyridazinyl), compound 68(R ═ 3-methyl-4-pyridazinyl) were each prepared according to a similar manner to example 22 using an appropriate halogenated nitrogen-containing heterocyclic group (halogen may be Cl or Br).
Example 23
Weighing diosgenin 4.2g, dissolving in tetrahydrofuran 100mL in a 500mL three-neck flask, adding triethylamine 10mL and 4-bromomethylpyridazine 2.2g, stirring, heating to 66 deg.C (heating reflux), reacting for 0.5h while maintaining the temperature, and detecting dioscin by TLCAll aglycones react, the temperature is raised to the room temperature, ethyl acetate is used for extracting for 3 times (100mL multiplied by 3), the pressure is reduced and the mixture is steamed until the liquid volume is 40mL, the mixture is cooled to 5 ℃, the crystallization is carried out overnight, the filtration is carried out, the TLC tracing reaction and the separation and purification process of the product are carried out, and the solid is dried for 4 hours at 60 ℃, so that 3.2g of light yellow powder product is obtained. Melting point of the target product: 184.0-186.0 ℃ of the total weight of the mixture,13C NMR(101MHz,CDCl3) δ 149.72,149.70,140.78,135.55,129.03,121.80,119.59,87.14,82.90,72.83,66.89,62.77,56.59,50.76,42.10,40.66,40.08,39.19,37.68,37.47,32.81,32.18,32.00,31.26,30.30,29.09,28.81,21.08,19.32,17.51,15.45, 14.77. TOF-HRMS: m/e (506.7178), formula: c32H46O3N2Compound 70 in table 1.
Compound 69(R ═ 3-pyridazinylmethyl) can be prepared by a method similar to that of example 23, using the appropriate halogenated nitrogen-containing heterocyclic group (halogen may be Cl or Br).
Example 24
Weighing 4.2g of diosgenin, dissolving in 100mL of dichloromethane in a 500mL three-neck flask, adding 10mL of diethylamine and 2.2g of 2-bromomethylpyrazine, stirring, reacting at 0 ℃ under heat preservation for 48h, detecting all reactions of the diosgenin by HPLC, evaporating the dichloromethane until the volume of the liquid is reduced to 1/4, cooling to 5 ℃ for crystallization overnight, filtering, tracing the separation and purification processes of the reaction and the product by HPLC, and drying the solid at 60 ℃ for 4h to obtain 3.1g of a yellow powdery product. Melting point of the target product: 182.5-184.4 ℃ of the total weight of the mixture,13C NMR(CDCl3100MHz) delta 153.75,144.81,143.85,142.43,140.86,121.88,119.67,87.10,82.98,71.82,66.97,62.85,56.67,50.84,42.18,40.74,40.16,39.27,37.75,37.55,32.89,32.26,32.08,31.34,30.38,29.17,28.89,21.16,19.40,17.59,15.83, 14.85. TOF-HRMS: m/e (506.7175), formula: c32H46O3N2Compound 73 in table 1.
Compound 71(R ═ 2-pyrazinyl) and compound 72(R ═ 3-methyl-2-pyrazinyl) can be prepared according to a similar procedure to that of example 24, using the appropriate halogenated nitrogen-containing heterocyclic group (halogen can be Cl or Br), respectively.
Example 25
Screening experiment for inhibitory activity on proliferation of bile duct cancer cell QBC-939 and human pancreatic cancer cell PANC-1
Collecting bile duct cancer cell QBC-939 and human pancreatic cancer cell PANC-1 with good growth state in logarithmic growth phase at 2 × 103Per 0.1 mL/well, plated in 96-well plates, each set of 5 parallel wells, 5% CO at 37 ℃2Culturing in incubator, culturing in culture solution containing 10% calf serum for 24 hr, and respectively changing to compound 1-73[ concentration of 0.2ug/mL ] in Table 1]The culture medium is continuously cultured, the culture medium is added into a negative group, 0.2ug/mL 5-fluorouracil (national drug group chemical reagent Co., Ltd.) is added into a control group 1, and 0.2ug/mL diosgenin (Aladdin chemical reagent Co., Ltd.) is added into a control group 2. After 24h of culture, adding 20uL (5mg/mL) of MTT (methanol to ethanol) for further culture for 4h, discarding the supernatant, adding 100uL of dimethyl sulfoxide (DMSO), oscillating for 10min, after the precipitate is completely dissolved, adjusting the wavelength to 570nm on an enzyme-linked detection analyzer, adjusting the blank to zero, measuring the OD value of each well, and repeating the steps for 3 times. The inhibition rate is (1-drug-added OD value/negative group OD value) × 100%
The synthesized typical compounds 1 to 73 and 5-fluorouracil have the inhibitory activity on the proliferation of bile duct cancer cells QBC-939 and human pancreatic cancer cells PANC-1, and the experimental results are shown in Table 2.
Figure BDA0002231304400000241
(R groups are shown in Table 2)
TABLE 2 inhibition of proliferation of bile duct cancer QBC-939 and human pancreatic cancer PANC-1 cells
Figure BDA0002231304400000242
Figure BDA0002231304400000251
Figure BDA0002231304400000261
Figure BDA0002231304400000271
Figure BDA0002231304400000281
Figure BDA0002231304400000291
Figure BDA0002231304400000301
Although the present invention has been described in detail with reference to the foregoing embodiments, it will be apparent to those skilled in the art that changes may be made in the embodiments and/or equivalents thereof without departing from the spirit and scope of the invention. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims (12)

1. A compound having the structure of formula (I):
Figure FDA0002682597560000011
wherein R is an unsubstituted or substituted nitrogen-containing heterocyclic group; the nitrogen-containing heterocycle is selected from pyrrole, thiazole, imidazole, pyrazole, oxazole, isoxazole, pyridine, pyrimidine, pyridazine and pyrazine; the substituent is selected from C1-3Alkyl, trifluoromethyl and carboxyl.
2. The compound of claim 1, wherein the substitution is mono-or di-substituted.
3. A compound according to claim 1 or 2, wherein R is selected from the group consisting of: 2-pyrrolyl, 3-pyrrolyl, 2-methyl-4-pyrrolyl, 2-imidazolyl, 4-methyl-2-imidazolyl, 2-methyl-4-imidazolyl, 3-pyrazolyl, 4-pyrazolyl, 5-methyl-3-pyrazolyl, 3-methyl-4-pyrazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 2-oxazolylmethyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 4-isoxazolyl, 3, 5-dimethylisoxazolyl-4-methyl, 2-imidazolyl, 4-pyrazolyl, 4-thiazolyl, 5-thiazolyl, 2-thiazolyl, 4-oxazolyl, 3-dimethylisoxazolyl-4-methyl, 2-oxazolyl, 3-dimethylisoxazolyl, 4-methyl, and mixtures thereof, 2-pyridyl group, 3-pyridyl group, 4-pyridyl group, 3-methyl-2-pyridyl group, 4-methyl-2-pyridyl group, 5-methyl-2-pyridyl group, 2-methyl-3-pyridyl group, 4-methyl-3-pyridyl group, 5-methyl-3-pyridyl group, 2-methyl-4-pyridyl group, 3-trifluoromethyl-2-pyridyl group, 4-trifluoromethyl-2-pyridyl group, 5-trifluoromethyl-2-pyridyl group, 2-trifluoromethyl-3-pyridyl group, 4-trifluoromethyl-3-pyridyl group, 5-trifluoromethyl-3-pyridyl group, 3-trifluoromethyl-pyridyl group, 3-pyridyl group, 4-trifluoromethyl-2-pyridyl group, 3-pyridyl group, 4-trifluoromethyl-pyridyl group, 3-, 2-trifluoromethyl-4-pyridyl group, 3-carboxy-2-pyridyl group, 4-carboxy-2-pyridyl group, 5-carboxy-2-pyridyl group, 2-carboxy-3-pyridyl group, 4-carboxy-3-pyridyl group, 5-carboxy-3-pyridyl group, 2-carboxy-4-pyridyl group, 3-pyridylmethyl group, 4-pyridylmethyl group, 2-pyrimidyl group, 4-pyrimidyl group, 5-pyrimidyl group, 4-methyl-2-pyrimidyl group, 5-methyl-2-pyrimidyl group, 2-methyl-4-pyrimidyl group, 3-carboxy-2-pyridyl group, 5-carboxy-3-pyridyl group, 2-methyl-5-pyrimidinyl, 2-pyrimidylmethyl, 4-pyrimidylmethyl, 5-pyrimidylmethyl, 3-pyridazinyl, 4-methyl-3-pyridazinyl, 5-methyl-3-pyridazinyl, 3-methyl-4-pyridazinyl, 3-pyridazinylmethyl, 4-pyridazinylmethyl, 2-pyrazinyl, 3-methyl-2-pyrazinyl and 2-pyrazinylmethyl.
4. A process for the preparation of the compound of claim 1, characterized in that; dissolving diosgenin in a solvent, adding RX and an alkaline substance to react, and keeping the solution alkaline in the reaction process to prepare a compound shown in a formula (I); wherein R is as defined in claim 1 or 3, X is halogen; the reaction temperature is-20-300 ℃, and the reaction time is 0.1-72 h;
the solvent is selected from one or more of water, methanol, ethanol, propanol, butanol, pentanol, glycerol, dichloromethane, trichloromethane, carbon tetrachloride, benzene, toluene, xylene, 1, 4-dioxane, 1, 2-dichloroethane, tetrahydrofuran, N-dimethylformamide, ethyl acetate and dimethyl sulfoxide;
the alkaline substance is selected from gamma-Al2O3-Na、γ-Al2O3-K、γ-Al2O3-NaOH-Na、γ-Al2O3-NaOH-K、γ-Al2O3-KOH-Na、γ-Al2O3-one or more of KOH-K, sodium methoxide, sodium ethoxide, sodium propoxide, sodium butoxide, sodium amide, sodium metal, sodium hydride, sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium oxide, potassium oxide, calcium oxide, strontium carbonate, potassium carbonate, sodium carbonate, potassium phosphate, ammonia, ethylamine, diethylamine, triethylamine, methylamine, dimethylamine, trimethylamine, pyridine, and piperidine.
5. A process according to claim 4, wherein the solvent is used in an amount such that each mole of diosgenin is dissolved in 5-100L of solvent.
6. The preparation method according to claim 4, wherein the molar ratio of the diosgenin, RX and alkaline substance is 1: (0.1-10): (0.01-10).
7. The preparation method of claim 6, wherein the molar ratio of the diosgenin, RX and alkaline substance is 1 (1.0-1.2) to (0.6-1.0).
8. The preparation method according to claim 4, further comprising detecting the end point of the reaction by chromatography, allowing the reaction product to stand at room temperature after the reaction is completed, and separating and purifying the product to prepare the compound of formula (I).
9. The method according to claim 8, wherein the separation and purification is performed by a method selected from the group consisting of filtration, resin treatment, water washing, distillation, crystallization, extraction, activated carbon treatment, molecular sieve treatment, and chromatography.
10. A composition comprising a compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof.
11. A pharmaceutical formulation comprising a compound according to any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof or a composition according to claim 10, together with at least one pharmaceutical carrier or adjuvant.
12. Use of a compound of any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof, or a composition of claim 10, or a pharmaceutical formulation of claim 11, in the manufacture of an anti-cancer medicament; the cancer is selected from pancreatic cancer and bile duct cancer.
CN201910968512.XA 2019-10-12 2019-10-12 Compound and preparation method and application thereof Active CN110746479B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910968512.XA CN110746479B (en) 2019-10-12 2019-10-12 Compound and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910968512.XA CN110746479B (en) 2019-10-12 2019-10-12 Compound and preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN110746479A CN110746479A (en) 2020-02-04
CN110746479B true CN110746479B (en) 2021-01-08

Family

ID=69278058

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910968512.XA Active CN110746479B (en) 2019-10-12 2019-10-12 Compound and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN110746479B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113018302B (en) * 2021-04-01 2023-09-05 河南中医药大学 Preparation method and application of self-assembled nanoparticles of diosgenin derivative and DHA
CN115558012B (en) * 2022-09-26 2024-05-17 湖南省中医药研究院 Dioscorea sapogenin-tanshinol derivative, self-assembled nanoparticle thereof, preparation method and application

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101787069A (en) * 2010-03-22 2010-07-28 四川大学 Diosgenin piperazine derivatives and preparation method thereof
CN110028546A (en) * 2019-03-30 2019-07-19 四川大学华西医院 The pentamethylene and more hydrogen phenanthrene framework compounds and application thereof of antitumor action are played with regulation factor VIII activity level
CN110028547A (en) * 2019-04-29 2019-07-19 中国药科大学 A kind of diosgenin 3-OH derivative and preparation method thereof and medical usage

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101787069A (en) * 2010-03-22 2010-07-28 四川大学 Diosgenin piperazine derivatives and preparation method thereof
CN110028546A (en) * 2019-03-30 2019-07-19 四川大学华西医院 The pentamethylene and more hydrogen phenanthrene framework compounds and application thereof of antitumor action are played with regulation factor VIII activity level
CN110028547A (en) * 2019-04-29 2019-07-19 中国药科大学 A kind of diosgenin 3-OH derivative and preparation method thereof and medical usage

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
《Synthesis and biological evaluation of novel 3-O-tethered triazoles of diosgenin as potent antiproliferative agents》;Masood-ur-Rahman;《Steroids》;20161115;第118卷;参见第5-7页3.2、scheme1、table1 *
《利用薯蓣皂甙元完整骨架形式合成1α,25-二羟基维生素D3》;林静容;《化学学报》;20070828;第65卷(第16期);参见第1686页第1.2节 *
《薯蓣皂苷元衍生物的抗肿瘤活性研究》;吴亚克;《华西药学杂志》;20121231;第27卷(第1期);参见第23页图1，第24页表1 *

Also Published As

Publication number Publication date
CN110746479A (en) 2020-02-04

Similar Documents

Publication Publication Date Title
CN110746479B (en) Compound and preparation method and application thereof
EP2787002B1 (en) Oleanolic acid amidate derivatives, preparation methods and uses thereof
CN114989139A (en) Process for preparing pyrimidine-2, 4-diamine dihydrochloride
EP2953951B1 (en) N2-substituted-n6-(6-aryl-pyridine-3-ylmethyl)-9-cyclopentyl-9h-purine-2,6-diamine derivatives as tumor suppressor p53 activators for inhibiting angiogenesis and for treating cancer
CN112010839B (en) Crystalline forms of a targeted silk/threonine kinase inhibitor
CN101624376B (en) Substituted hydrazide compound and application thereof
JP3763414B2 (en) Crystal form of N- {2-chloro-4-[(6,7-dimethoxy-4-quinolyl) oxy] phenyl} -N '-(5-methyl-3-isoxazolyl) urea salt
CN111777595A (en) Novel crystal form of cyclohexane carboxamide compound and preparation method thereof
WO2016023330A1 (en) Quinazoline derivative
CN110520425B (en) EOC315Mod.I crystal form compound and preparation method thereof
CN109776553B (en) Fuhexine and preparation method and application thereof
CN111689947B (en) tegafur-L-proline co-crystal and preparation method thereof
EP4219476A1 (en) Salt of arylaminoquinazoline-containing compound, and preparation method therefor and use thereof
WO2011143864A1 (en) Anticancer compounds and preparation methods thereof
CN110092789B (en) Indolo [2,3-b ] carbazole derivative and application thereof
KR102606167B1 (en) Fluorine-containing substituted benzothiophene compounds, pharmaceutical compositions and applications thereof
CN110642918B (en) Diosgenin derivative and preparation method and application thereof
CN113045554A (en) Fexotinib crystal form and preparation method thereof
CN109678872B (en) Bisbenzylisoquinoline compound and preparation method and application thereof
CN110577563B (en) Fluorine-containing compound, preparation method thereof and application thereof in preparation of antitumor drugs
CN113801118A (en) Pteridinone derivatives as RSK inhibitors and application thereof
CN113801139A (en) Pyrimido-oxazine derivatives as RSK inhibitors and uses thereof
US20160145262A1 (en) New polymorphic forms of icotinib phosphate and uses thereof
WO2020216188A1 (en) Crystal forms of compound, preparation method therefor, pharmaceutical composition and application thereof
CN112279863A (en) Conjugate of Hsp90 inhibitor and camptothecin derivative as well as preparation method and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant